Syngene

Ref: Syn/CS/SE/IP/2026-27/Jul/18

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.
T +91 80 6891 9191
CIN: L85110KA1993PLC014937
www.syngeneintl.com

July 29, 2026

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	**Scrip Symbol: SYNGENE**

Dear Sir/Madam,

Sub: Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter ended June 30, 2026. The Company will use this presentation for any meeting scheduled with analysts or institutional investors.

The above-mentioned Investor Presentation will also be available on the website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

CHETHAN YOGESH Digitally signed by CHETHAN YOGESH Date: 2026.07.29 21:12:04 +05'30'

Chethan Yogesh
Company Secretary and Compliance Officer

Enclosed: Investor Presentation.

Syngene
Putting Science to Work

Investor Presentation

July 2026

Safe harbour

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.

Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts, our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India.

Neither the Company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Contents

1 Q1 FY27 Highlights

Q1 FY27 performance

Operating Highlights

- Siddharth Mittal assumed charge as Managing Director & CEO on July 1, 2026
- Signed a Memorandum of Understanding (MoU) with BRIC-Translational Health Science and Technology Institute (THSTI), an institute under the Biotechnology Research Innovation Council (BRIC), Department of Biotechnology, Ministry of Science and Technology, Government of India. The collaboration establishes a joint operational partnership for early and late-phase clinical development, translational research and bioanalytical sciences
- Further strengthened Syn.AI, Syngene's AI-enabled scientific platform for accelerating drug discovery services. Syngene developed gigascale virtual screening capabilities, enabling larger libraries of molecules to be screened and prioritized, helping clients identify promising drug candidates faster. Syngene also advanced its AI-driven de novo (new molecule) design capabilities, enabling faster design and optimization of novel drug candidates
- Featured in TIME Magazine and Statista's "World's Most Sustainable Companies 2026" ranking for the second consecutive year. Selected from more than 5,800 companies across 43 countries, Syngene was ranked among the world's top 750 most sustainable companies and continues to be recognized as one of the leading pharmaceutical and biotechnology companies globally

Q1 FY27 Financial Highlights

Revenue from Operations	Rs 736 Cr (-16% Y-o-Y)
Operating EBITDA margin	12% (24% in Q1 FY26)
PAT, before exceptional items[1]	Rs. 1 Cr
PAT, after exceptional items	Rs -9 Cr

- Our performance during the quarter was primarily impacted by the lack of offtake from a major LMCDMO client and forex hedge loss, partially offset by our ongoing cost optimization initiatives.
- While we expect a degrowth in the first half of the fiscal year, business momentum is expected to improve in the second half, resulting in single-digit revenue degrowth in rupee terms for the full year and EBITDA margins in the mid-20s

[1]Excludes expenses of Rs 10 Cr (net of tax) recognised under Exceptional Items related to termination benefits extended to employees in accordance with the approved policy

2 Syngene – Putting Science to Work

Partner in innovation: #Putting Science to Work

Who we are and what we do

We aim to be a world class partner delivering innovative scientific solutions for clients

We offer integrated solutions across research, development and manufacturing

Sector expertise include pharmaceuticals, biotech, nutrition, animal health, consumer goods and specialty chemicals

Our team includes more than ~5,700+ scientists out of total 8,300+ headcount, operating across 4 global state-of-the-art campuses located in India's leading life science hubs: Bangalore, Mangalore, Hyderabad and USA (Baltimore)

Established track record in discovery research and development/ manufacturing for small and large molecules

Our journey so far

1993 – 2000

Foundation

- Operations started
- Expansion of R&D Lab
- Granted 100% EOU status by the Government of India

2001 – 2009

Expansion

- Expanded service offerings to include chemical development, safety assessment, biologics development
- Collaboration with BMS to set up BBRC, Syngene's first dedicated R&D Center

2010 – 2014

Globalization and strategic collaboration

- Expanded into formulations development
- Contract with Endo Pharmaceuticals to develop novel anti cancer biological therapeutic molecules
- Extension of collaboration with BMS;
- Merger of Clinigene
- Crossed annual turnover of Rs. 5 Billion

2015 – 2018

IPO and further collaborations

- IPO and listing
- Collaboration with Amgen to set up a dedicated R&D center

2019 – 2026

Continued investments and growth

- Laboratory capacity expansion in Bangalore and Hyderabad
- Expansion in Mangalore for commercial API manufacturing
- Capacity and capability addition in Biologics manufacturing
- Entered in long-term partnership with Zoetis for Biologics commercial-scale manufacturing
- Acquired multi-modal biologics manufacturing facility from Stelis Biopharma Ltd
- Acquired 17 acres land in Hyderabad to support long term growth in research business
- Acquired, state of the art first biologics site in Baltimore, USA taking Syngene's total single-use bioreactor capacity to 50,000L
- Invested in new capabilities and emerging modalities, such as peptides and ADCs, ensuring alignment with growing global demand

Key facts and figures

~400
active clients

16 out of top **20**
pharma companies are clients

400+
patents
held with clients

World class infrastructure
International presence with global campuses across Bangalore, Hyderabad and Mangalore in India and Baltimore in USA qualified to meet international standards

Rs. 3,739 Cr
FY26 Revenue from operations

Rs. 380 Cr*
FY26 PAT

8,373 headcount
including **5,778**
talented scientists

92%
energy from
renewable sources

All figures are as on March 31, 2026 / FY2026, unless otherwise specified
**before exceptional items*

Syngene – one of the largest integrated CRDMO players in India

One-stop platform for integrated drug discovery, development and manufacturing across modalities

Expanding capacity

(in Million sq. ft.)

More than tripled the infrastructure that is qualified to meet international standards

- *Expanded laboratory capacity in Bangalore and Hyderabad*
- *Expanded to Mangalore for commercial API manufacturing*
- *Acquired land in Hyderabad for long term growth in research business*
- *Acquired multi-modal biologics facility from Stelis Biopharma Ltd*
- *Acquired first biologics site in the USA from Emergent Manufacturing Operations Baltimore, LLC*
- *US FDA, EMA, UK VMD, Health Canada, PMDA approved, AAALAC accredited and GLP certified facilities*

Building capabilities for future

(#)



Over 2.5x employees from FY16 comprising talented scientists

- *~5,700+ scientists comprising PhDs, MS*
- *Skills and experience to become trusted thought partner in cutting-edge research*
- *Scientific prowess across modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs*
- *Proven success in delivering integrated CMC programs and clinical candidates*

Building partnerships

(#)

Over 50% increase in active clients

16 out of top 20 pharma companies are clients

- *Expanded partnerships with big pharma and emerging biopharma*
- *Expanded into commercial manufacturing in Biologics with Zoetis*
- *Enhanced BD presence across key value clusters including US and Europe*
- *25-year strategic partnership with BMS – established BBRC, India's first and largest dedicated R&D center*

3-pronged growth strategy across diversified platform

Research Services (CRO)

Discovery Services

Flexible Platform with capability across multiple modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs

SynVent - proprietary platform for Integrated Drug Discovery

SARchitect- proprietary platform for data visualization and analysis. Enables collaboration between scientific experts across geographies

Dedicated R&D Centers

Ring-fenced infrastructure for exclusive operations for an individual client

Dedicated multi-disciplinary team of scientists

Access to entire Syngene ecosystem for specialist research and development operations

T&CR

Comprehensive research services through trials conducted on both healthy volunteers and patients

- Human Pharmacology Unit (Phase I/BE studies)
- Clinical Trial Services – full solution provider for conducting global trials
- Translational services- a continuum from preclinical to clinical trials
- Regulated bioanalysis for large and small molecules
- Central Laboratory

Large Molecule CDMO

Process development

Manufacturing of large molecules for clinical/commercial supplies

Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate

cGMP-compliant facilities

State-of-the art Biologics manufacturing facilities with international presence

Small Molecule CDMO

Drug substance and drug product development

Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate

cGMP-compliant manufacturing of clinical supplies, and registration batches for small molecules

Manufacturing of small molecules for commercial supplies

State-of-the art API manufacturing facility

Our Strategy

Research Services

Provide an integrated end-to-end therapeutic discovery services Encompassing drug discovery, pre-clinical and clinical development capabilities across technologies, platforms, disciplines, disease areas and therapeutic modalities.

Development and Manufacturing Services – Large Molecules

Implement a comprehensive strategy for biologics development and manufacturing, establishing a seamless, one-stop-shop capability that covers everything from drug discovery to commercial production.

Development and Manufacturing Services – Small Molecules

Utilize existing Chemistry, Manufacturing, and Controls (CMC) capabilities and commercial manufacturing, while also developing innovative technologies, to establish a fully integrated, cutting-edge small molecule development and manufacturing service provider

Operational Excellence

Drive operational excellence through improved reliability, speed and efficiency to enhance customer delivery and satisfaction.

People

Build a future ready, high-performance organization by nurturing leadership at all levels, fostering holistic employee well-being, and driving a culture of continuous growth and innovation

Environmental, Social and Governance (ESG)

Syngene is committed to responsible and sustainable growth, ensuring that its ESG standards meet the evolving expectations of clients, investors, and stakeholders. Our ESG strategy is a key enabler of long-term value creation, embedding environmental stewardship, social responsibility, and robust governance across all aspects of our operations

3

Syngene strengths

Syngene strengths

A global scale CRDMO player

- Integrated Drug Discovery, Development and Manufacturing service provider
- Small and large molecules, ADCs, oligonucleotides
- Listed on Indian Stock Exchanges (NSE and BSE)

Science in our DNA

- Global presence : India life science hubs: Bangalore, Mangalore and Hyderabad & Baltimore, USA
- ~5700+ qualified scientists including ~500 PhDs (8,300+ total headcount)
- Resilient supply chain management
- ~3 Mn sq. ft world-class R&D and manufacturing infrastructure

Solutions through innovation

- IP fully assigned to clients
- Track record of data management and security
- Over 400+ patent filings by clients recognizing Syngene scientists

Blue chip client list

- ~400 active clients
- Partnering with large / mid-size / emerging biopharma and other industries
- Clients concentrated in US, Europe & Japan
- Track record of working with diverse industry sectors

Quality matters

- Fully digitized quality organization
- Strong compliance track record with global regulators
- US FDA, EMA, UK VMD, Health Canada, PMDA approved, AAALAC accredited and GLP certified facilities
- 85 client and regulator audits in the last financial year

Making a difference

- Partnerships have delivered numerous clinical candidates
- Delivery history for integrated CMC programs up to clinical trials and beyond

Experienced workforce: building capabilities and careers

***8,373** total headcount*

***5,778** scientists delivering high quality solutions – create a competitive edge*

7% PHDs

Inspiring technical excellence and providing opportunities to grow

Empowering our workforce

- **Thrive360 operating philosophy** embedding wellbeing into how work is designed and delivered - supporting physical, mental & emotional, social, financial and career wellbeing
- **Future-focused performance and career conversations** that build capability, clarify growth pathways and strengthen engagement and retention

Continuous learning & development

- **Enterprise-wide leadership and manager capability development** to build strong people leadership and succession depth
- **Scientific skills development** to standardise and advance scientific and technical upskilling across the organization
- Supporting **talent stability and execution** continuity during a demanding operating environment

Shaping a culture of belonging

- **Inclusive culture** broadening access to scientific and leadership talent
- **Diverse teams** strengthening innovation and problem-solving
- **27%** women representation overall and **19%** women in senior management

All figures are as on March 31, 2026

Extended our state-of-the-art infrastructure & new capabilities with global presence to meet our strategic partners needs

HQ campus at Bangalore, India
where most of Syngene's capabilities are housed today

Biologics
Discovery development & and manufacturing plants in Bangalore, India

Fully functional R&D Centre at
Genome Valley, Hyderabad, India

API manufacturing
Commercial manufacturing to support product launch located at Mangalore, India

USA based Biologics facility
Bayview, Baltimore, USA

We currently operate a range of successful collaboration models

1 Dedicated R&D Labs

- Customers receive ring-fenced infrastructure customized to their research needs
- Dedicated scientific and support teams work exclusively on the customer's projects
- Long-term strategic partnerships, typically extending for five years or more, foster deep collaboration and sustained innovation

2 Full time equivalent (FTE)

- A dedicated team of scientific personnel from predefined disciplines works exclusively on the customer's projects
- Deliverables and team composition evolve as the project progresses to align with changing requirements
- Agreements are typically renewed annually, ensuring continuity and flexibility

3 Fee For service (FFS)

- Services are provided within a defined scope
- Flexible, on-demand personnel and research infrastructure are allocated to meet project objectives
- Engagements can be short-term or long-term, based on project requirements

4 Risk / Reward Model

- A milestone-driven approach covering a portfolio of research projects
- Customers benefit from reduced upfront costs, with payments tied to predefined success milestones

5 Outcome – based model with Service Level Agreement

- A contract structured around the achievement of predefined outcomes
- Linked to specific productivity goals to ensure performance-driven results

… and are open to any single or combination of above

Our experience spans multiple industry segments and partners us with global leaders across the world…

Large & Mid-Sized BioPharma

Bristol Myers Squibb
GSK
sanofi
NOVARTIS
AMGEN
MERCK
Boehringer Ingelheim
Baxter

Emerging BioPharma (EBP)

Albireo AN IPSEN COMPANY
AMPHISTA THERAPEUTICS
Genmab
ASCENEURON
PharmAust LIMITED
saniona
C4 Therapeutics

Animal Health

IVAOES ANIMAL HEALTH
Phibro
zoetis
Elanco
MERCK Animal Health

AgroChem

FMC
DOW
Dow AgroSciences

CPG

Givaudan
PURINA

Chemicals/ Polymers

essilor
Beiersdorf
KRATON

Note : This is a representative selection of the customers Syngene works with. We work with ~ 400 customers across industry segments .All product names, logos, brands, trademarks and registered trademarks are the property of their respective owners

Operational robustness driving strategy execution

Continuous improvement embedded through a structured Lean Six Sigma framework

Certification pathway from White Belt to Master Black Belt
90+ Green Belts and 60+ Black Belts driving operational excellence
10+ Master Black Belts anchoring enterprise-level transformation

Focused execution through strong Project Management

Structured program management for executing client projects enabled by SynPro platform and SynPro Academy ensuring delivery of client projects



Quality management system: digitized and audit-ready

85 customer and regulator audits in the last FY
6 successful USFDA audits in the last 5 years

Digital as a differentiator

AI capability in all research teams
Integrating automation, IT solutions, and data analytics, we optimize workflows, enhance resource allocation and utilization, and ensure regulatory compliance

Client-focused commercial organization

Leaders based in the US, Europe, UK and Asia close to client locations

Strategic Sourcing that makes a difference

Effective global collaboration with 2,800+ suppliers across 30 countries

Building a resilient supply chain amid geopolitical uncertainty through robust logistics network, dual sourcing strategy, and domestic supplier development for critical raw materials.

Syngene digital initiatives aimed at driving innovation and operational

At Syngene, IT strategy is closely aligned with organizational priorities, emphasizing investments in automation and digitization to improve scientific and enterprise functions.

Certification as per ISO 13485:2016, ISO/IEC 27001 and ISO 9001:2015 requirements

Driving Enterprise-Wide Transformation

Initiatives to automate and integrate core business processes, enhancing Syngene's digital presence and customer engagement.

Accelerating Digital Transformation at Syngene

Comprehensive 1-3-5-year roadmap to future-proof operations and build next-generation digital capabilities, with an emphasis on AI adoption

Strengthening Scientific Operations

Automate workflows, eliminate errors, and improve execution quality

Enabling AI-Powered Productivity

"Fail fast" approach to AI and GenAI, launching small-scale pilots to quickly test feasibility, assess early outcome

Fortifying Infrastructure and Information Security

Advanced IT and cybersecurity landscape with a One-Click Disaster Recovery system, CDC & ISWG

Committed to safety and sustainability

Safety is our first priority

- Accredited with ISO 45001:2018 for Occupational Health and Safety (OH&S) measures
- Risk assessments are an integral part of our operation
- Kavach, our flagship safety program, has delivered improvement in safety metrics and drives focus on industrial safety for all employees
- Lost time injury frequency rate (LTIFR): 0.03
- 35,365 hours of EHSS training

Proud to be recognized by TIME Magazine and Statista as:

- **World's Most Sustainable Companies 2025**
- **World's Best Companies in Sustainable Growth 2026**
- **World's Most Sustainable Companies 2026**

ESG Rating Performance

ESG Rating Agency	FY25	FY24	FY23
EcoVadis	Silver (91st percentile)	Silver (86th percentile)	Bronze (65th percentile)
CDP	B (Water Security) B (Climate Change)	B (Water Security) B (Climate Change)	D (Water Security) C (Climate Change)
Sustainalytics	14.7 Low Risk	15.6 Low Risk	12.4 Low Risk
MSCI	A	BB	BBB
DJSI	76	50	N/A

Committed to environmental protection

- Achieved 61% reduction of SBTi Scope 1 & 2 emissions, exceeding target of 54.6%
- 95% of energy procured from renewable energy sources
- 73,741 tCO_2e of GHG emissions avoided
- ISO 50001:2018 Energy Management Certificate for Bengaluru & Mangaluru
- 97% of total hazardous and non-hazardous waste recycled
- Zero waste to direct landfill
- 58% YoY freshwater savings achieved
- 1,14,633 KL fresh water saved from recycling, reusing and rainwater harvesting
- 2,231 KL rainwater harvested

Refer to the [CSR link] on our website to know about our corporate social responsibility pursuits on healthcare, education, environment, rural development
Refer to the [Annual Report] on our website to know more
All figures are as on March 31, 2026, unless otherwise specified

Accreditations

- USFDA, EMA, UK VMD, PMDA and Health Canada Certified GMP facilities.
- GLP, NABL (ISO IEC 17025) certification for Safety Assessment and Large Molecule Bioanalytical Laboratory
- GLP certification for Viral Testing Facility, AAALAC Accreditation and CCSEA registration for Safety Assessment
- USFDA, MHRA. AGES inspected & ANVISA approved Translational and Clinical research facility
- ISO 15189:2012, NABL & College of American Pathologists (CAP) accredited Clinical and Molecular diagnostics facility
- ISO 9001:2015, 14001:2015, 45001:2018, ISO 13485:2016, ISO 50001:2018 and ISO/IEC 27001:2022 accreditations.

We have consistently received industry recognition for our scientific capability and business excellence

2021

- **Dream Companies to Work Award** at the 29th Edition of the World HRD Congress Awards.
- **Asian Leadership Award for Excellence in Branding and Marketing** in the Contract Research Development and Manufacturing category
- **CRISIL awards Syngene Top score among Indian Pharma** - for Environment Safety Governance (ESG)
- **Syngene ranked #69 in Fortune India magazine's** list of 'Top 100 Indian wealth creators 2021'
- **India Pharma Awards 2021** for Operational Excellence– Manufacturing organized by Informa Markets, India
- **Best Governed Company in the Listed Segment: Medium Category** at the 21st National Awards for Excellence in Corporate Governance by The Institute of Company Secretaries of India (ICSI)
- **Best Corporate Foundation Award** at the World CSR Congress

2022

- **CMO Leadership Awards 2022** Presented by Life Science Leader and Outsourced Pharma
- **CMO Leadership Award Champion 2022 -** Presented by Life Science Leader and Outsourced Pharma
- **Golden Peacock Award for Excellence in Corporate Governance** for 2021 by the Institute of Directors at the 'Golden Peacock Awards Ceremony'
- **The 2022 Brandon Hall Group HCM Excellence Bronze Award** In Leadership Development for 'Best Unique or Innovative Leadership Program' and 'Best Advance in Compliance Training'
- **The 2022 Brandon Hall Group HCM Excellence Bronze Award** In Leadership Development for
- **Asia Pacific Biologics CMO Excellence Awards 2022 -** For Quality
- **Biopharma Honours Award 2022 -** For Viral Testing Facility by Informa Markets
- **Most Preferred Workplace 2022 -** Award by MarksmenDaily.com

2023

- **Golden Peacock National Quality Award 2023** For meeting the overall requirements of the Golden Peacock Excellence Model
- **Biopharma Excellence Awards** 2023 For Best Contract Development and Manufacturing Organization (CDMO)

2024

- **EcoVadis Sustainability Rating, 2024 :** Syngene secured silver rating in the EcoVadis sustainability index for commitment to ESG practices and ranked among the top 15% of companies assessed worldwide.
- **Asia Pacific Biologics CMO Excellence Awards 2024** : Adjudged Best Biologics CMO in South Asia by IMAPAC
- Winner under the Reliability and Compatibility categories for exceeding customer expectations at **CDMO Leadership Awards 2024**
- Declared champion by the Institute of Supply Chain Management (ISCM) at the **Pharma Supply Chain Management 5.0 summit**.
- Award for Excellence in Environment Health and Safety (EHS) practices at **CII-SR EHS Excellence Awards 2023**
- Awarded **India's Best Managed Compan**y by Deloitte
- **Golden Peacock Award 2023:** For risk management practices under the Pharmaceutical sector category.
- **Best Overall Sustainable Performance (Pharmaceutical) 2023** at the 2nd Edition India Sustainability Conclave & Awards 2023

2025-2026

- **CDMO Leadership Award 2025**: Adjudged winner in the Biologics category by Outsourced Pharma and Life Science Connect.
- **Biopharma Excellence Awards 2025 (India Edition)**: Adjudged Best Bioprocessing Supplier – Analytical Services by IMAPAC.
- **Pharma Supply Chain Champion 2025:** Ranked #1 among mid-sized pharma and API firms by the Institute of Supply Chain Management (ISCM).
- **TIME Magazine & Statista – World's Most Sustainable Companies 2026**: Ranked amongst the global top three and #1 in India in the Pharma & Biotech category; second recognition in six months.
- **S&P Global Sustainability Yearbook 2026:** Ranked among the top 10 life sciences companies and the top 9% globally; recognised as an 'Industry Mover' for or achieving the highest year-on-year improvement in its Corporate Sustainability Assessment score.
- **NAMC Gold Award**: Biologics Manufacturing Excellence at the National Awards for Manufacturing Competitiveness (NAMC).
- **Achieved My Green Lab 'Green Certification' (>94% score)** for laboratories
- **EcoVadis 2025 score** improved to 74/100, placing Syngene in the 91st percentile globally.

Note : This is a representative selection of awards received by Syngene and is not an exhaustive list

Syngene has established an enterprise-wide risk oversight with clear accountability from management to the Board

Syngene's enterprise-wide risk management framework provides a holistic approach to identification, monitoring, reporting and mitigating risks that could impact performance

Operating Unit / Enabling Function Heads
Operational execution and risk ownership

- Own the identification and management of risks
- Review risk registers and track mitigation actions
- Escalate emerging risks and threshold breaches to the Executive Committee
- Align risk actions with operational priorities and performance goals

Executive Committee
Strategic alignment and execution

- Align risk management with strategic objectives, business planning and resource allocation
- Identify and review key risks and their mitigation effectiveness
- Promote cross functional risk collaboration

Risk Management Committee
Governance and oversight

- Oversee risk management policy and framework
- Define and monitor risk appetite in co-ordination with the Board
- Monitor risk exposure against defined limits
- Review risk identification, assessment and rating processes
- Evaluate the effectiveness of internal controls

Board of directors
Strategic oversight

- Define and approve risk appetite statements
- Set strategic direction for risk management
- Assess the performance of the Risk Management Committee and overall ERM processes

Refer Annual report for complete risk profile and risk mitigation strategy

4 Financials

Q1 FY27 financial highlights

All figures in Rs. Cr unless otherwise specified

Particulars	Q1 FY27	Q1 FY26	YoY change
Revenue from operations	**736**	**875**	**-16%**
Other income	25	18	43%
Reported revenue	**761**	**892**	**-15%**
Material costs	173	218	-20%
Staff costs	281	291	-3%
Other direct costs	30	26	15%
Other expenses	110	128	-14%
Foreign exchange (gain)/loss, net	50	5	>100%
EBITDA	**116**	**224**	**-48%**
EBITDA Margin	***15.2%***	***25.1%***	
Operating EBITDA Margin (ex-other income)	***12.3%***	***23.6%***	
Depreciation and Finance Cost	112	111	1%
PBT	**-6**	**101**	**-106%**
Tax	-7	15	-146%
PAT before exceptional items	**1(1)**	**87**	**-99%**
PAT Margin	***0.1%***	***9.7%***	
PAT after exceptional items	**-9**	**87**	**-110%**

(1) Excludes expenses of Rs 10 Cr (net of tax) recognised under Exceptional Items related to termination benefits extended to employees in accordance with the approved policy
(2) Other Net Assets calculated as all assets other than cash and cash equivalents less all liabilities other than debt and shareholders equity
(3) Net cash / (Net debt) calculated as the Cash & cash equivalents (Cash and bank balances + Current investments+ Fixed deposits) less Total debt (Short-term borrowings + Long-term borrowings) at the end of the year

Balance Sheet Highlights

As on 30th June 2026

All figures in Rs. Cr unless otherwise specified

Shareholders' funds	**4,866**
Net Fixed assets	4,010
Other net assets (2)	-685
Net cash/(debt) (3)	1,541
Total Use of Funds	**4,866**

FY26 financial highlights

All figures in Rs. Cr unless otherwise specified

Particulars	FY26	FY25	YoY change
Revenue from operations	**3,739**	**3,642**	**3%**
Other income	71	71.8	-1%
Reported revenue	**3,809**	**3,714**	**3%**
Material costs	919	943	-3%
Staff costs	1,230	1,079	14%
Other direct costs	103	97	6%
Other expenses	508	480	6%
Foreign exchange (gain)/loss, net	61	2	3104%
EBITDA	**989**	**1,114**	**-11%**
EBITDA Margin	***26.0%***	***30.0%***	
Operating EBITDA Margin (ex-other income)	***24.6%***	***28.6%***	
Depreciation and Finance Cost	453	433	5%
PBT	**488**	**628**	**-22%**
Tax	108	153	-30%
PAT before exceptional items	**380**(1)	**475**(2)	**-20%**
PAT Margin	***10.0%***	***12.8%***	
PAT after exceptional items	**317**	**496**	**-36%**

Balance Sheet Highlights

As on 31st March 2026

All figures in Rs. Cr unless otherwise specified

Shareholders' funds	**4,839**
Net Fixed assets	4,046
Other net assets (3)	-1,007
Net cash/(debt) (4)	1,800
Total Use of Funds	**4,839**

(1) Excludes (i) impact of Rs. 38 Cr. (net of tax) pertaining to the net increase in gratuity liabilities on account of newly implemented labour codes, and (ii) expenses of Rs 25 Cr. (net of tax) recognised under Exceptional Items related to termination benefits extended to employees in accordance with the approved policy.
(2) Excludes an exceptional item of Rs 21 Cr. (net of tax) relating to the final settlement from an insurance claim.
(3) Other Net Assets calculated as all assets other than cash and cash equivalents less all liabilities other than debt and shareholders equity
(4) Net cash / (Net debt) calculated as the Cash & cash equivalents (Cash and bank balances + Current investments+ Fixed deposits) less Total debt (Short-term borrowings + Long-term borrowings) at the end of the year

5 Shareholding and Share Information

Syngene and Biocon Group

Syngene is an operationally independent publicly listed subsidiary of Biocon Limited, established in 1993 as India's first Contract Research Organization. The Company has 30+ years of experience in novel molecule discovery, development and manufacturing services

Biocon Limited, founded in 1978, is an innovation-led global biopharmaceuticals company and has majority holding in key operating entities including Syngene

Syngene

Integrated services:

- Research Services
- Development and for
- Manufacturing small/large molecules

- Product Based
- Biosimilars
- Formulations and Compounds
- Alternative Therapeutic Drugs

Biocon

Shareholding and Share Information

Syngene's shareholding*



Syngene's Share Information*

NSE Ticker	SYNGENE
BSE Ticker	539268
Market Cap (Rs. Cr)	17,741
% free-float^	47%
Free-float market cap (Rs. Cr)	8,411
Share Outstanding (Cr)	40

- *As on 30st June 2026*
- *^ Free float includes shares held by public and in ESOP Trust*

For more details

Visit our website www.syngeneintl.com

https://www.linkedin.com/company/syngene-international-limited

https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ

IR Contact:
Nandini Agarwal
investor@syngeneintl.com
nandini.agarwal@syngeneintl.com

Media Contact:
Vijay Jeevanandham
E: Vijay.jeevanandham@syngeneintl.com